CN104997873A - Traditional Chinese medicine food for treating diseases of prostate and preparation method thereof - Google Patents
Traditional Chinese medicine food for treating diseases of prostate and preparation method thereof Download PDFInfo
- Publication number
- CN104997873A CN104997873A CN201510498320.9A CN201510498320A CN104997873A CN 104997873 A CN104997873 A CN 104997873A CN 201510498320 A CN201510498320 A CN 201510498320A CN 104997873 A CN104997873 A CN 104997873A
- Authority
- CN
- China
- Prior art keywords
- prostate
- preparation
- chinese medicine
- traditional chinese
- prostatosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine food for treating diseases of prostate and a preparation method thereof. The traditional Chinese medicine health care food comprises the following raw materials in parts by weight: 35-65 parts of loquat and 30-70 parts of carrot. The preparation method comprises the following steps: washing loquat and carrot, peeling and denucleating the loquat, peeling the carrot, stripping and slicing the loquat and carrot, juicing and uniformly mixing to obtain the traditional Chinese medicine food. The traditional Chinese medicine food is free of toxic or side effect, can effectively treat prostatitis and benign prostatic hyperplasia, is obvious in effect, and provides a novel choice for health care foods or medicines for preventing or treating prostatitis.
Description
Technical field
The present invention relates to field of health care products, specifically a kind of Chinese medicinal food for the treatment of prostatosis and preparation method thereof.
Background technology
Prostate is as Semen Castaneae, and the end upward, is affixed with bladder, point down, to urogenital diaphragm, before paste pubic symphysis, after according to rectum, so when having prostatauxe, can rectal touch be done, the prostatic back side of stereognosis.The centre of prostate gland has urethra to pass, and it is suitable for reading to hold urethra, so prostate is ill, urinates first influenced.But along with the increase at age, male easily suffers from prostatosis, mainly comprise prostatic hyperplasia and prostatitis.
Prostatitis refers to prostate specific and the active chronic inflammation caused by non-specific infection, thus the whole body caused or local symptom.Harm: 1) painful, affects work and life.Due to the stimulation of inflammation, produce series of symptoms, as the position distending pains such as waist sacrum, perineum, testis, urine retention, nocturia frequency etc., make patient's dysphoria, affect work and life.2) affect sexual function, cause sexual impotence, premature ejaculation.Because disease fails to cure for a long time, various symptom and discomfort increase the weight of after intercourse, or directly affect impression and the quality of sexual life, cause a kind of pernicious stimulation to patient, gradually occur a kind of detest sense, cause the phenomenon such as sexual impotence, premature ejaculation.3) impact fertility, can cause sterile.Long-term chronic inflammatory disease, prostatic fluid composition is changed, and prostatic secretions function is affected, and then affects the liquefying time of seminal fluid, and motility of sperm declines, and can cause male sterility.4) cause chronic nephritis, even can develop into uremia.Prostatitis, as treated not in time, can cause prostatic hyperplasia, oppress bladder outlet, urine can not be emptied completely, occur residual urine.Residual urine is vegetative good culture medium, and mucous membrane of urinary bladder defense mechanism is impaired in addition, therefore very easily causes urinary tract infection as pyelonephritis etc., now as treatment is not thorough, by pyelonephritis, hydronephrosis etc., and then develops into nephritis, finally develops into uremia.5) cause endocrine disturbance, cause psychological problem.Under normal circumstances, prostate can secrete various active material.Because prostate is inflamed, endocrine disturbance, can cause neurasthenia, so that spirit occurs abnormal; Also the symptoms such as insomnia and dreamful sleep, weak dizziness, bradyphrenia, hypomnesis can be there is.6) infect spouse and cause gynecological inflammation.Prostatitis can be transmitted to wife, particularly the prostatitis that causes of some special courses of infection, and its inflammation can by sexual intercourse route infection to wife.As mycotic prostatitis, trichomonal prostatitis, gonococcal prostatitis, non-gonococcal (chlamydia, mycoplasma) prostatitis etc.7) easily infection is caused.Containing a kind of antibiotic substance in human prostate, be prostate antimicrobial factors.When prostate inflammation, this antimicrobial factors reduces, so easily cause infection.The infection that prostatitis causes can cause acute urinary retention, acute seminal vesiculitis or epididymitis, deferentitis, spermatic cord lymphadenectasis or tenderness etc., time serious, inguiodynia or renal colic can occur.8) easily tumor is suffered from.U.S.'s data in 1985 thinks that oncogene is most important factor, and virus is also the possible cause of disease.Find in the U.S.'s one group of retrospective study, exist between prostate and incidence of Gonorrhea and there is contacting of statistical significance, thus the cause of disease proposing carcinoma of prostate is relevant with viral sexually transmitted disease (STD) and chronic infection.Current research shows, containing a kind of cancer-resisting substance in normal human prostate liquid, significant to Tumor suppression.And prostate ill time this cancer-resisting substance reduce, thus easily cause tumor.
Pathology and the analysis pathology prostate of prostatic hyperplasia divide inside and outside two-layer: internal layer is periurethral mucosa and submucosal glands; Skin is body of prostate.The latter forms prostatic main body, has fibrous membrane to separate between two-layer.Prostatic hyperplasia mainly occurs in internal layer, in the body of gland interstitial of neck of bladder to seminal colliculus one section of Posterior urethral, now claims this part to be that transitional zone microscopy is visible.The prostate of hypertrophy makes neck of bladder block, and bladder is strengthened contraction make detrusor generation compensatory plumpness in little beam-like projection for being overcome cervical region resistance.Bladder cavity is intrinsic pressure to be increased, and mucous membrane of urinary bladder outwards can swell by weakness between muscle bundle, forms diverticulum obstruction at vesical neck.Continue to increase the weight of, urine will residue in bladder to some extent, and with increasing of residual urine, the wall of urinary bladder gradually thinning physiological flap valve effect that ureter lower end diagonal is formed through wall of urinary bladder muscle layer lost efficacy.Just adverse current is to ureter and renal pelvis for intravesical urine, and cause urinary tract hydrops on both sides, Renal pelvic pressure increases, and makes the atrophy of excess of the kidney matter ischemic, causes renal hypofunction finally uremia to occur.
Although Current therapeutic prostatic hyperplasia, prostatitic medicine are more, both mostly are chronic disease, if long-term prescription, can bring otherwise negative effect to patient body.If can be theoretical according to the traditional Chinese medical science " integration of edible and medicinal herbs ", a kind of determined curative effect, good mouthfeel and be convenient to industrial prostatosis dietary product be provided, will bring glad tidings for patient.
Summary of the invention
The object of the present invention is to provide Chinese medicinal food of a kind of effective treatment prostatosis and preparation method thereof, to solve the problem proposed in above-mentioned background technology.
For achieving the above object, the invention provides following technical scheme:
Treat a Chinese medicinal food for prostatosis, be made up of the following raw material according to weight portion: Folium Eriobotryae 35-65 part, Radix Dauci Sativae 30-70 part.
As the further scheme of the present invention: the Chinese medicinal food of described treatment prostatosis, be made up of the following raw material according to weight portion: Folium Eriobotryae 45-55 part, Radix Dauci Sativae 45-55 part.
As the further scheme of the present invention: the Chinese medicinal food of described treatment prostatosis, be made up of the following raw material according to weight portion: Folium Eriobotryae 50 parts, 50 parts, Radix Dauci Sativae.
The preparation method of the Chinese medicinal food of described treatment prostatosis, is made up of following steps: Folium Eriobotryae, Radix Dauci Sativae are cleaned, and Folium Eriobotryae is removed the peel enucleation, and Radix Dauci Sativae is removed the peel, and then stripping and slicing, squeezes the juice, and makes preparation and get final product after mixing.
As the further scheme of the present invention: described preparation is tablet, granule, capsule, pill or oral liquid.
Folium Eriobotryae in the present invention, have another name called husky Singapore, that Palmae (Palmae or Arecae) Folium Eriobotryae belongs to (Sa-lacca) plant, English " salak " or " snake fruit " by name, Classification system is " Salacca zalacca (Gaertner) Voss ", having another name called " Salacca edulis Reinw ", is the famous fruit in Southeast Asia.Folium Eriobotryae is containing protein, carbohydrate, calcium, fat, ferrum, vitamin (B1) and vitamin (C2).Folium Eriobotryae is very delicious, and taste is fresh and sweet, tasty and refreshing.The sarcocarp of Folium Eriobotryae is that white middle band is yellow, but to bite away be very sharp and clear sensation, and meat very the universe is hard, very sour and astringent.Folium Eriobotryae has the effect of beauty treatment.Loquat fruit contains human body skin beneficiating ingredient, and it often eats as beauty treatment fruit by the local Miss of Indonesia.It is one of kind that in fruit, potassium content is the highest, and pectin content is also very abundant, very useful to human brain.
Containing abundant carotene in Radix Dauci Sativae; the free radical that one is removed blood, blood and intestinal in human body can be played; the effect of a prevention and cure of cardiovascular disease can be reached; Radix Dauci Sativae is also containing abundant sugar reducing substance simultaneously; as Quercetin, these two kinds of elements of kaempferol just can play the effect that increases coronary artery blood flow, have very large help to reduction blood fat; adrenergic synthesis can also be promoted, the effect of protection cardiovascular health.Radix Dauci Sativae is contained in abundant vitamin A, and speckle dispelling keeps the elasticity of skin.Radix Dauci Sativae also has effect of liver-benefiting eye-brightening.Lignin in Radix Dauci Sativae can improve the immunity of body, simultaneously when carotene is converted into the immunologic function that vitamin A also contributes to enhancing body, plays the effect that is eliminated cancerous cell indirectly.Radix Dauci Sativae promotes intestinal health, enhances metabolism, and promotes blood circulation, slow down aging.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention is nontoxic, have no side effect, and can effectively treat prostatitis and prostatic hyperplasia, and effect obviously, for prevention or treat prostatitic health product or medicine provides a kind of selection newly.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, be clearly and completely described the technical scheme in the embodiment of the present invention, obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Chinese medicinal food for the treatment of prostatosis, is made up of the following raw material according to weight portion: Folium Eriobotryae 35 parts, 70 parts, Radix Dauci Sativae.
The preparation method of the Chinese medicinal food of described treatment prostatosis, be made up of following steps: Folium Eriobotryae, Radix Dauci Sativae are cleaned, and Folium Eriobotryae is removed the peel enucleation, Radix Dauci Sativae is removed the peel, then stripping and slicing, to squeeze the juice, make tablet, granule, capsule, pill or oral liquid after mixing and get final product.
Embodiment 2
In the embodiment of the present invention, a kind of Chinese medicinal food for the treatment of prostatosis, is made up of the following raw material according to weight portion: Folium Eriobotryae 65 parts, 30 parts, Radix Dauci Sativae.
Preparation process as described in Example 1.
Embodiment 3
In the embodiment of the present invention, a kind of Chinese medicinal food for the treatment of prostatosis, is made up of the following raw material according to weight portion: Folium Eriobotryae 45 parts, 55 parts, Radix Dauci Sativae.
Preparation process as described in Example 1.
Embodiment 4
In the embodiment of the present invention, a kind of Chinese medicinal food for the treatment of prostatosis, is made up of the following raw material according to weight portion: Folium Eriobotryae 55 parts, 45 parts, Radix Dauci Sativae.
Preparation process as described in Example 1.
Embodiment 5
In the embodiment of the present invention, a kind of Chinese medicinal food for the treatment of prostatosis, is made up of the following raw material according to weight portion: Folium Eriobotryae 50 parts, 50 parts, Radix Dauci Sativae.
Preparation process as described in Example 1.
Beneficial effect of the present invention is illustrated below by way of test example.
Test example 1 the present invention is to the effect of prostatic hyperplasia
1. experiment material
1.1 laboratory animal
Kunming mouse, the quality certification number: scxk (river) 2008-24.SD rat, the quality certification number: scxk (river) 2008-24
1.2 Experimental agents and reagent
Test medicine: prepared by embodiment 5.
Test medicine grouping and dosage: high dose group of the present invention: 46.50g/ (kgd); Middle dosage group: 23.25g/ (kgd); Low dose group: 11.63g/ (kgd), is equivalent to 5 times of the clinical consumption per day of normal type 60kg people, 10 times, 20 times respectively.
Blank group: 0.9% normal saline gavages.
Aspirin: Hefei Jiu Lian pharmaceutical Co. Ltd produces, and batch number: 20110108, faces with aspirin being formulated as 60mg/ml suspension for subsequent use.
Indomethacin: Chongqing Ke Rui pharmaceutical Co. Ltd produces, and batch number: 09060l, faces with indomethacin being formulated as 2.5mg/ml suspension for subsequent use.
Dimethylbenzene: Chengdu Ke Long chemical reagent factory, lot number: 20100116.
QIANLIEKANG: Zhejiang Kang Enbei drugmaker produces, lot number: 930211.Face the suspension with QIANLIEKANG being formulated as 75mg/ml.
2. experimental technique
2.1 modeling of experimental rat prostatic hyperplasia and medications
Literature method is imitated in the modeling of prostate model, get healthy male SD rat 90, random taking-up 20 rat skin lower injection equal-volume normal saline, as solvent control group, all the other 70 whole subcutaneous injection Testosterone Propionate 3.5mg/ (kgd), successive administration 25d.Then get 10 rats at random from Testosterone Propionate group, empty stomach 12h together with normal saline group 10 rats, after 45mg/kg pentobarbital sodium injecting anesthetic, accurately take body weight, take prostate to weigh, with prostate ponderal index (body of gland weight/body weight), become large evaluation index as prostatic hyperplasia, compare with between t method of inspection group.
After determining that experimental group prostate obviously increases, experimental group 60 rats are divided into 6 groups, i.e. model group at random, estradiol group, QIANLIEKANG positive controls, the high, medium and low dosage group of the present invention.Blank group gives equal-volume normal saline, after successive administration treats 4 weeks, ditto takes empty body weight and weight of prostate, to compare between prostate ponderal index group, evaluates the therapeutical effect of medicine.
2.2 data statistics
Experimental data spss13.0 statistical software process, indices all represents with mean plus-minus standard deviation, compares and adopt t inspection between each group.
3. experimental result
3.1 the present invention are to the effect of experimental rat prostatic hyperplasia
As can be seen from experimental result, the high, medium and low dosage group of QIANLIEKANG group, test medicine all can reduce the benign prostatic hyperplasia in rats (P < 0.05) that testosterone propionate causes.Illustrate that the present invention is inhibited to prostatic hyperplasia.Experimental result is in table 1.
Table 1 the present invention is on the impact of benign prostatic hyperplasia in rats
Note: compare with model group: * * P < 0.01; * P < 0.05
4. discuss
Show by testing above, the present invention has significantly suppression and therapeutical effect to prostatic hyperplasia.
Test example 2 the present invention is on prostatitic impact
1. experiment material is as test example 1.
2. experimental technique
2.1 the present invention are to the effect of Rat Experimental chronic prostatitis
The foundation of chronic prostatitis model: get SD male rat 60,50 under strict sterilization, with amobarbital sodium intraperitoneal injection of anesthesia (100mg/kg).Anaesthetize successfully, take off median abdominal incision under aseptic condition, through abdominal cavity proposes bladder and both sides spermatic cord, exposes the prostate notopodium invested inside seminal vesicle, injects 1% carrageenin normal saline solution 0.1mL suture muscles, skin respectively.Another 10 under equal conditions row sham-operation contrast.Under guarantee conditions of water drinking, plain particles word material is fed.
Experimental technique: we select postoperative 4d according to preliminary result, i.e. inflammation peak period, 50 rats are divided at random high dose group of the present invention, middle dosage group, low dose group, every day, empirically 2.1.1 gavage gave to test medicinal liquid, positive drug group gavage gives indomethacin suspension, and chronic prostatitis model group and rats in sham-operated group fill with the distilled water of same volume.After successive administration 30d, after last administration 30min, anaesthetize with amobarbital sodium, cut open the belly and get prostatic fluid 10 μ L and put into leukocyte diluent, microscopy unit volume leukocyte count, separately gets prostatic fluid 1, smear, observe and record lecithin density, disconnected ridge is put to death rat and is got the observation of prostata tissue specimen subsequently.
2.2 data statistics
Experimental data spss13.0 statistical software process, indices all represents with mean plus-minus standard deviation, compares and adopt t inspection between each group.
3. experimental result
3.1 the present invention are to the effect of Rat Experimental chronic prostatitis
As can be seen from experimental result, after modeling, each group rat prostate liquid total white blood cells obviously raises, and lecithin density obviously reduces.Have connective tissue and smooth muscle between sham operated rats prostate gland, lumen of gland form is irregular, many pleats, and epithelial cell height differs, how in column, flat or cube.There is obvious statistical significance compared with sham-operation, show modeling success.After the administration of continuous 30 days, prostatic fluid total white blood cells and the lecithin density of the present invention's high, middle dosage group rat are obviously improved, and prostatic fluid total white blood cells is comparatively model group reduction obviously, and lecithin density is comparatively model group rising obviously.Through statistical procedures, there is statistical significance.Show that the present invention has the effect of certain treatment Rat Experimental chronic prostatitis.Experimental result is in table 2.
Table 2 the present invention is on the impact of prostatic fluid total white blood cells and lecithin density
Note: compare with Sham-operated control group: * * P<0.01; * P<0.05; Compare with model group: △ △ P<0.01; △ P<0.05.
4. discuss
Show by testing above, the present invention has good therapeutical effect to prostatitis.
In sum, the present invention can effectively treat prostatic hyperplasia and prostatitis, and effect obviously, provides a kind of selection newly for preventing or treating prostatic hyperplasia and prostatitic health product or medicine.
To those skilled in the art, obviously the invention is not restricted to the details of above-mentioned one exemplary embodiment, and when not deviating from spirit of the present invention or basic feature, the present invention can be realized in other specific forms.Therefore, no matter from which point, all should embodiment be regarded as exemplary, and be nonrestrictive, scope of the present invention is limited by claims instead of above-mentioned explanation, and all changes be therefore intended in the implication of the equivalency by dropping on claim and scope are included in the present invention.
In addition, be to be understood that, although this description is described according to embodiment, but not each embodiment only comprises an independently technical scheme, this narrating mode of description is only for clarity sake, those skilled in the art should by description integrally, and the technical scheme in each embodiment also through appropriately combined, can form other embodiments that it will be appreciated by those skilled in the art that.
Claims (5)
1. treat a Chinese medicinal food for prostatosis, it is characterized in that, be made up of the following raw material according to weight portion: Folium Eriobotryae 35-65 part, Radix Dauci Sativae 30-70 part.
2. the Chinese medicinal food for the treatment of prostatosis according to claim 1, is characterized in that, is made up of the following raw material according to weight portion: Folium Eriobotryae 45-55 part, Radix Dauci Sativae 45-55 part.
3. the Chinese medicinal food for the treatment of prostatosis according to claim 2, is characterized in that, is made up of the following raw material according to weight portion: Folium Eriobotryae 50 parts, 50 parts, Radix Dauci Sativae.
4., according to the preparation method of the Chinese medicinal food of the arbitrary described treatment prostatosis of claim 1-3, it is characterized in that, be made up of following steps: Folium Eriobotryae, Radix Dauci Sativae are cleaned, and Folium Eriobotryae is removed the peel enucleation, Radix Dauci Sativae is removed the peel, and then stripping and slicing, squeezes the juice, and makes preparation and get final product after mixing.
5. the preparation method of the Chinese medicinal food for the treatment of prostatosis according to claim 4, is characterized in that, described preparation is tablet, granule, capsule, pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510498320.9A CN104997873A (en) | 2015-08-12 | 2015-08-12 | Traditional Chinese medicine food for treating diseases of prostate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510498320.9A CN104997873A (en) | 2015-08-12 | 2015-08-12 | Traditional Chinese medicine food for treating diseases of prostate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104997873A true CN104997873A (en) | 2015-10-28 |
Family
ID=54370911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510498320.9A Pending CN104997873A (en) | 2015-08-12 | 2015-08-12 | Traditional Chinese medicine food for treating diseases of prostate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104997873A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670687A (en) * | 2011-06-01 | 2012-09-19 | 成都六木保健品科技开发有限公司 | Health care product composition or drug composition for preventing or treating prostatic diseases |
| KR101373653B1 (en) * | 2012-02-07 | 2014-03-14 | 한국인스팜(주) | A composition comprising the extract of Rosa rugosa for preventing and treating benign prostatic hyperplasia |
-
2015
- 2015-08-12 CN CN201510498320.9A patent/CN104997873A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670687A (en) * | 2011-06-01 | 2012-09-19 | 成都六木保健品科技开发有限公司 | Health care product composition or drug composition for preventing or treating prostatic diseases |
| KR101373653B1 (en) * | 2012-02-07 | 2014-03-14 | 한국인스팜(주) | A composition comprising the extract of Rosa rugosa for preventing and treating benign prostatic hyperplasia |
Non-Patent Citations (1)
| Title |
|---|
| 康成: "《男科病如何用药与食物疗法》", 30 November 2013 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102441081B (en) | Medicament for treating gout and its preparation method | |
| CN101579119A (en) | Nutritional food with function of relaxing bowel and preparation method thereof | |
| CN103751716B (en) | A kind of pharmaceutical composition for the treatment of renal calculus and cholelithiasis | |
| CN105166545A (en) | Bovine compound feed and preparation method thereof | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN108853258A (en) | A kind of Chinese medicine composition that treating functional consitipation and its application | |
| CN102319353A (en) | Traditional Chinese drug enema for treating abdominal distension after gynecological operation | |
| CN102526640B (en) | Pantoprazole sodium medicine compound and preparation technology thereof | |
| CN104721672A (en) | Traditional Chinese medicine preparation for treating adhesive intestinal obstruction and preparation method thereof | |
| CN102670687B (en) | Health care product composition or drug composition for preventing or treating prostatic diseases | |
| CN104958488A (en) | Health product for preventing or treating prostate disease and preparation method of health product | |
| CN104857091A (en) | Traditional Chinese medicine composition for treating renal calculus | |
| CN104940718A (en) | Pharmaceutical composition for treatment of chronic cholecystitis and preparation method thereof | |
| CN104474456B (en) | A kind of traditional Chinese medicine pill for being used to treat fibroid | |
| CN103432540B (en) | The five internal organs, which are adjusted, mends ball | |
| CN103181559A (en) | Nutritious food with bowel nourishing and purgation functions and preparation method thereof | |
| CN104997873A (en) | Traditional Chinese medicine food for treating diseases of prostate and preparation method thereof | |
| CN106177773B (en) | A kind of Chinese medicinal pill for treating calculi in urinary system | |
| CN104771627B (en) | A kind of Chinese medicine composition for treating the prolapse of uterus | |
| CN103495119B (en) | Medicament for treating qi stagnation and blood stasis chronic prostatitis | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN103893679A (en) | Traditional Chinese medicine composition for treating nervous tinnitus and preparation method thereof | |
| CN105362780A (en) | Compound traditional Chinese medicine oral solution for treating infantile functional constipation | |
| CN105194635A (en) | Traditional Chinese medicine composition for navel therapy for treating child diarrhoea and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151028 |